Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Study Finds Bacterial Antigen Critical in Lethal Effects of Infection, Provides Clues for Therapy

By BiotechDaily International staff writers
Posted on 27 Aug 2013
A predominant molecular cause underlying lethal forms of infective endocarditis, sepsis, and kidney damage that often result from Staphylococcus aureus infection has been found, as well as indications for prevention and treatment therapies.

According to a study by a collaborative team at the University of Iowa (Iowa City, Iowa, USA) and the University of Minnesota (Minneapolis, MN, USA), the major superantigen (SAg) produced by S. aureus, staphylococcal enterotoxin C (SEC), is also a major cause of these severe conditions. Using the methicillin-resistant S. aureus (MRSA) strain MW2, the team showed that lethal sepsis, infective endocarditis and acute kidney infections in rabbits are critically dependent on high-level SAgs. SAgs, particularly SEC, were found to have a critical role in the development of all three conditions and that the association results from both superantigenicity and direct toxic effects on endothelial cells, the latter likely contributing to delayed endothelium healing. In contrast, the isogenic strain lacking SEC was found to be attenuated in virulence, and complementation with SEC restores disease production.

Infective endocarditis resulting from staph infection has a mortality rate of about 40%–50%, and about half of the surviving patients will suffer a stroke. The study showed that SEC not only over activates the immune system, but that this “excessive immune response is actually contributing very significantly to the destructive aspects of the disease, including capillary leakage, low blood pressure, shock, fever, destruction of the heart valves, and strokes that may occur in half of patients," said Patrick Schlievert, PhD, professor and chair of microbiology at the UI Carver College of Medicine. In addition to effects of excessive immune response, the SAgs also appear to have direct toxic effects, in part via endothelial cell stimulation.

Treatment therapeutics and prevention by vaccination are potential strategies for blocking these harmful effects. "We have high affinity molecules that neutralize superantigens and we have previously shown in experimental animals that we can actually prevent strokes associated with endocarditis in animal models. Likewise, we have shown that we can vaccinate against the superantigens and prevent serious disease in animals," said Prof. Schlievert. Also, low blood flow via the infection site appears to be one of the consequences of SEC’s action. The team found that increasing blood pressure by fluid replacement therapy reduced the formation of vegetations (the plaque-like meshwork made up of bacteria and host cell factors) on the heart valves and significantly protected from infective endocarditis, possibly also by washing away significant amounts of the superantigen molecule itself.

The study was published online August 20, 2013, in the American Society for Microbiology journal mBio.

Related Links:

University of Iowa
University of Minnesota
US National Institutes of Health



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.